Gabapentin Has Been Linked to Dementia Risk in Recent Observational Studies
Based on emerging evidence, gabapentin use is associated with an increased risk of dementia, particularly with prolonged use, higher cumulative doses, and in patients with chronic kidney disease. The most recent and highest-quality evidence shows a dose-dependent relationship, with the risk amplified in specific vulnerable populations 1, 2, 3.
Evidence Summary
Recent Research Findings
The strongest recent evidence comes from multiple large observational studies:
A 2026 systematic review and meta-analysis found gabapentin use associated with modestly higher odds of dementia (OR 1.28,95% CI 1.10-1.50), though this association attenuated when restricted to low-risk-of-bias studies (OR 1.23,95% CI 0.83-1.84). The certainty of evidence was rated as low due to high heterogeneity and potential confounding 1.
A 2026 cohort study of 33,791 patients demonstrated that chronic kidney disease dramatically amplifies gabapentin-associated dementia risk (HR 7.39 in CKD patients vs. HR 1.09 in non-CKD patients). Critically, this elevated risk persisted even at low doses (≤300 mg), suggesting standard renal dose adjustment may be insufficient 2.
A 2025 study of chronic low back pain patients found that six or more gabapentin prescriptions increased dementia risk (RR 1.29) and mild cognitive impairment (RR 1.85). The risk was particularly pronounced in non-elderly adults aged 18-64 (RR 2.10 for dementia, RR 2.50 for cognitive impairment) and increased further with prescription frequency 3.
A 2023 Taiwanese population study of 206,802 patients showed gabapentin/pregabalin exposure increased dementia risk (HR 1.45,95% CI 1.36-1.55) in a dose-dependent manner, with younger patients (<50 years) showing the highest risk (HR 3.16) 4.
Contradictory Evidence
One 2024 nested case-control study from Taiwan found no significant association between gabapentin use and dementia risk (adjusted OR 0.91,95% CI 0.83-1.01) 5. However, this single study is outweighed by multiple recent studies showing positive associations.
Clinical Implications
High-Risk Populations
Patients requiring particular caution:
- Those with chronic kidney disease (especially non-dialysis CKD stages G3b-G4), where gabapentin half-life extends 10-20 fold 2
- Younger adults (<65 years), who paradoxically show higher dementia risk 3, 4
- Patients requiring long-term therapy (≥6 prescriptions or 12+ months) 3
- Those receiving higher cumulative doses 4
Guideline Context
While current guidelines recognize gabapentin's role in neuropathic pain management 6, they do not specifically address dementia risk. The 2024 ADA guidelines emphasize screening for cognitive impairment in older adults with diabetes and note that diabetes itself increases dementia risk 7. The 2021 polypharmacy guidelines discuss deprescribing strategies but do not specifically flag gabapentin for dementia risk 8.
FDA Labeling
The FDA label for gabapentin warns of CNS depression, somnolence, and dizziness but does not currently include dementia as a labeled risk 9. However, observational data on hypnotics and benzodiazepines have shown associations with dementia (HR 2.34) 10, establishing precedent for cognitive concerns with GABAergic medications.
Practical Recommendations
When prescribing gabapentin:
Assess renal function before initiation and monitor regularly—CKD amplifies risk substantially, even with dose adjustment 2
Consider pregabalin as an alternative in patients with CKD, as its pharmacokinetic profile shows less dramatic accumulation (4-fold vs. 10-20 fold half-life extension) 2
Limit duration when possible—risk increases with cumulative exposure, particularly beyond 6 prescriptions 3
Monitor cognitive function in all patients, especially those <65 years old who show paradoxically higher risk 3, 4
Weigh alternatives for chronic pain: duloxetine for neuropathic pain, topical NSAIDs for localized pain, or acetaminophen for mild-moderate pain 6
Screen for dementia annually in older adults per ADA guidelines, with particular attention in gabapentin users 7
Important Caveats
- Causality remains unproven—all evidence is observational with potential for confounding by indication (chronic pain itself may increase dementia risk) 1
- Heterogeneity is high across studies, limiting confidence in pooled estimates 1
- Confounding by indication is difficult to eliminate—patients prescribed gabapentin may have underlying conditions that independently increase dementia risk
- The mechanism linking gabapentin to dementia is unclear but may involve chronic CNS depression, drug accumulation in renal impairment, or direct neurotoxic effects 2
The evidence suggests exercising caution with gabapentin, particularly for long-term use, in patients with CKD, and when effective alternatives exist. While not definitively causal, the consistency of findings across multiple large studies warrants clinical vigilance and consideration of alternative pain management strategies when appropriate.